Larimar Therapeutics (LRMR) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Larimar Therapeutics is the larger company by market cap ($281.0 million vs $269.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | VOGX |
|---|---|---|
| Share price | $2.71 | $18.17 |
| Market cap | $281.00M | $269.92M |
| 1-day change | +0.19% | +3.89% |
| YTD return | -29.13% | — |
| 1-year return | -43.98% | — |
| 5-year return | -77.72% | — |
| EPS (TTM) | $-1.99 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $38.41 |
| 52-week low | $2.61 | $12.95 |
| Distance from 52-week high | -57.87% | -52.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +432.35% | +202.70% |
| Average volume | 1.27M | 187.66K |
| Shares outstanding | 103.88M | 14.86M |
| Employees | 71 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
LRMR vs VOGX FAQ
Which is bigger, Larimar Therapeutics or Vogenx?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $281.00M compared with $269.92M for Vogenx (VOGX).
Are Larimar Therapeutics and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.